La Jolla Riquent NDA Planned For Year-End; Will Seek Accelerated Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
La Jolla Pharmaceuticals will pursue accelerated approval for its systemic lupus erythematosus agent Riquent (formerly LJP 394).